Rokote Laboratories

Phase 1

Turku, FinlandFounded 2020rokote.com

The first vaccine developed using this platform, FINVAC COVID-19, is a nasal vaccine against SARS-CoV-2 and is preparing to enter its second clinical trial.

Market Cap

Private

Pipeline

—

Patents

—

Publications

—

Private Company

Funding information not available

About

The first vaccine developed using this platform, FINVAC COVID-19, is a nasal vaccine against SARS-CoV-2 and is preparing to enter its second clinical trial.

Vaccines